1. Overview
  2. All Stocks
  3. GH Research PLC

GH Research (GHRS.US) Price Target 2026/2027: 100% Upside – Rating and Stock Analysis

21.52
Analysis framework by , founder of TradeDesk · Data: EODHD, insider trades from SEC Form 4 filings · Updated
Price history for GH Research (GHRS.US) – stock price at $21.52, October 2026
GH Research stock price – price development 2026. Updated Oct 7, 2026.
Share this analysis:

GH Research Price Target 2026: Analysts See 99% Upside

The average price target for GH Research is $42.89. This price target represents the analysts' view of the stock price over the next 12 months. The stock may be undervalued, because the price target is higher than the current price. The stock is 99.30% below the target, which can point to potential returns within the next 12 months if the analysts' view proves right. Also consider the stock's valuation ratios such as P/E, P/S and P/B, plus the technical analysis further down the page, for the full picture.

Is GH Research overvalued or undervalued?

GH Research is currently undervalued with a gap of 99.3% relative to the price target.


The current price is $21.52, which places GH Research in the undervalued category. The stock is considered undervalued when the price is below $38.60, and overvalued when the price exceeds $47.18.


The fair value range is defined as ±10% of the price target, because price targets are estimates rather than exact values. For GH Research, the fair value range lies between $38.60 and $47.18.


See the full price target analysis for GH Research →

↑ Back to navigation

Analyst Ratings for GH Research stock in 2026: Strong Buy

8 analysts cover GH Research. There is broad agreement on a positive view — 100% recommend buying. The average price target is $42.89, which gives an upside of 99.3% from the current price.

Consensus: Strong Buy (4.63/5)
Strong Buy
5 (62.5%)
Buy
3 (37.5%)
Strong Sell Sell Hold Buy Strong Buy
4.63 out of 5 based on 8 analysts
↑ Back to navigation

About GH Research – Biotechnology

GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland. Read more about the company

Key Figures for GH Research

$1.6B Market cap
- Revenue
Biotechnology Industry
- P/E
- P/S
4.96 P/B
United States Listed on exchange
ghres.com Website
Healthcare Sector

What kind of stock is GH Research?

Speculative stock

GH Research is classified as a speculative stock.

Score Overview for GH Research

💰 Value Score 8/100 (Very Low)
⭐ Quality Score 10/100 (Very Low)
🚀 Momentum Score 37/100 (Low)
📊 Total Score 18/100

⚠️ 3 red flags identified 1 critical

Our analysis has identified 3 potential risk factors in GH Research that investors should be aware of.

🚨 Weak financial health: The Piotroski score is only 1/9 – the company shows signs of weakened profitability, liquidity or capital structure.
⚠️ Negative return on equity: ROE is -18.8% – the company is generating a negative return for shareholders.
⚠️ High short interest: 10.0% of the shares are sold short – many professional investors are betting on price declines.

📈 Valuation

The P/B ratio is 5.0.

🏦 Financial Health

The Piotroski score is 1 out of 9 — weak financial health, be careful. Altman Z2 is 32.81 (healthy balance sheet — low risk). The debt-to-equity ratio (D/E) is 5.2% — low debt, a solid balance sheet.

🚀 Momentum & Short Interest

Short interest is 10.04% — very high, the market is skeptical.

↑ Back to navigation

GH Research Short Selling 2026: 10.0% Sold Short

Very high short interest: 10.0% of the free float
Short % of free float
10.0%
Assessment
Very high short interest
Short squeeze risk
High
Data source
EODHD
Reported about twice a month

Short interest over time: GH Research

0.0%6.7%13.4%
Peak 11.7% · 8/27
8/49/210/2
10.0% today (very high)Peaked at 11.7% on Aug 27, 2026Last 30 days: −1.7 percentage pointsMeasured over 59 days
What does the trend tell you?
Short interest is falling. It is down 1.7 percentage points over the last month and now stands at 10.0%. This is how shorting works: whoever shorts has borrowed the share and sold it, and to close the position again they must buy the share back. Falling short interest therefore means shares are being bought back in GH Research right now.

Many investors watch for exactly this: short interest that has been high and starts falling back. The professionals who bet on a falling price are closing down. That is not in itself a signal about what the price will do — we cannot predict the market, and short interest is only one number among many. But it does say something about what the large players are doing.
The stock has a very high share of short selling. Between 10-20% of the freely traded shares are sold short, which points to considerable bearish sentiment. A positive earnings report or unexpectedly good news can trigger a short squeeze with sharp price gains.

What does this mean for you as an investor?
A short interest of 10.0% means that 10.0% of the freely traded shares in GH Research have been borrowed and sold by investors betting on falling prices. On positive surprises (e.g. a strong earnings report), short sellers can be forced to buy back shares quickly to close their positions, which can cause a short squeeze with sharp price gains in a short time.

The next potential catalyst is the earnings report on Nov 5, 2026. With a short interest of 10.0%, the report can trigger considerable volatility.

Short interest comes from our data provider EODHD. The figure is reported about twice a month; we check it every trading day.
Short Interest Scale
0% 2% 5% 10% 20%+
Low Moderate High Very High Extreme
▲
10.0%

↑ Back to navigation

When Does GH Research Report Earnings – Next Date: Nov 5, 2026

The next earnings report from GH Research is scheduled for November 5, 2026, before the market opens. This report covers the third quarter (Q3), which ended on September 30, 2026.



↑ Back to navigation

Technical Analysis of GH Research 2026 – Signal: Hold

Overall Technical Signal: Hold

Based on trend analysis (SMA50/SMA200) and MACD trend (positive/negative on a daily + weekly basis). Updated October 7, 2026.

Technical analysis of GH Research (GHRS.US) – RSI 26, MACD negative (bearish), daily candlestick chart October 2026
GH Research technical analysis – candlestick chart with RSI, MACD and volume profile. Updated Oct 7, 2026.

Trend Analysis of GH Research PLC

GH Research PLC is in a short-term downtrend. The price of $21.52 is 16.2% below the 20-day average ($25.67). Medium term, the picture is negative: the price is 21.7% below the 50-day average ($27.50). Long term, the stock is 2.2% above the 200-day average ($21.06), which confirms a long-term uptrend.

Golden Cross: The 50-day average (27.50) is above the 200-day average (21.06), which is a classic bullish signal for GH Research PLC.

Is GH Research PLC overbought or oversold?

GH Research PLC has an RSI of 26.4, which places the stock in oversold territory (below 30). The trend is neutral, so the oversold level should be interpreted with caution. Wait for confirmation from MACD or a trend reversal.

MACD Analysis for GH Research PLC

Daily MACD: MACD is negative (-1.540), which means the short-term trend is bearish (the 12-day EMA is below the 26-day EMA). MACD is below the signal line (-1.088) by 0.452, which confirms growing negative momentum in the downtrend.

Weekly MACD: MACD5 is positive (1.906), which indicates a broader bullish long-term trend. MACD5 is below the signal line (2.796) by 0.890, which suggests the long-term momentum is fading – the positive trend could come under pressure.

Overall MACD assessment: The daily and weekly MACD give conflicting signals. The long-term trend is bullish, but the short-term trend is bearish. Short-term momentum is still falling – a deeper pullback is possible.

Risk Profile for GH Research PLC

GH Research PLC has an annual standard deviation of 71.9%, which classifies the stock as Extremely speculative. Only risk-tolerant investors should consider this stock, because the price swings can be very large.

Overall Technical Conclusion for GH Research PLC

Trend: Neutral/mixed.

MACD trend (zero line): Daily bearish (-1.540). Weekly bullish (1.906).

MACD momentum (signal): Daily falling. Weekly falling.

RSI: 26.4 – oversold.

Technical signal: Hold

The signals are mixed – trend and MACD point in different directions. Wait until MACD crosses the zero line in the direction of the trend before acting.

↑ Back to navigation

Frequently Asked Questions About GH Research stock in 2026

Should you buy GH Research stock now?
The technical signal for GH Research is currently Hold. GH Research trades at $21.52 as of Oct 7, 2026. The technical analysis shows the following: MACD is negative (bearish trend) at -1.540 with falling momentum (signal: -1.088); RSI is at 26.4 (oversold), which could point to a potential buying opportunity; the stock is in a short-term downtrend (price below the 20-day average); the analyst price target of $42.89 points to 99.3% upside. This is a technical observation based on current data, not investment advice.
What is the price target for GH Research stock?
The average analyst price target for GH Research is $42.89. The current price is $21.52, which gives an upside of 99.3%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $38.60 and $47.18.
Is GH Research a dividend stock?
No, GH Research does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of GH Research stock?
GH Research is rated as a stock in the risk category Extremely speculative. the annual standard deviation is 71.9%, which classifies the stock as Extremely speculative. In addition, an RSI of 26.4 signals oversold (potential bottom).
Is GH Research overvalued?
No, GH Research is considered undervalued based on the analyst price target (99.3% upside). GH Research has the following valuation ratios: a P/B ratio of 5.0. The analyst price target suggests that the stock is undervalued by 99.3%.
Is GH Research overbought?
No, GH Research is actually oversold with an RSI of 26.4 (below 30). The technical indicators show: RSI is at 26.4 (below the 30 mark), which actually signals the price is oversold – the opposite of overbought. In addition, the price is 16.2% below the 20-day average (short-term downtrend). In addition, MACD is negative with falling momentum (bearish).
When is the next GH Research earnings report?
GH Research reports its next earnings on November 5, 2026. The stock currently trades at $21.52. The RSI is at 26.4, so the report can reinforce the current technical trend.
Is GH Research shorted?
Yes, GH Research is shorted with 10.0% of the free float sold short. This is a very high level of short selling, which points to considerable bearish sentiment. A positive earnings report or unexpectedly good news can trigger a short squeeze with sharp price gains. The figure comes from our data provider EODHD, is reported about twice a month, and we check it every trading day.
Are insiders buying GH Research stock?
There is currently no registered insider trading for GH Research.
Is GH Research a good stock?
Based on our total score, GH Research is rated as a disastrous stock with a total score of 18 out of 100. The stock scores very low on value, quality and momentum – it is among the worst in our database. The score is made up of Value: 8/100, Quality: 10/100, Momentum: 37/100. In addition: analysts see 99.3% upside to the price target; technical signal: Hold. Whether GH Research is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for GH Research stock?
The outlook for GH Research based on current data: the average analyst price target is $42.89 (+99.3%); the next earnings report is due on Nov 5, 2026, which can move the price. Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is GH Research stock falling?
GH Research is falling right now. The technical indicators show: the price is 16.2% below the 20-day average; MACD is negative with falling momentum (bearish signal); short interest is 10.0% (high – many are betting on a decline). For the latest context, see our technical analysis and insider section above.
How high can GH Research go?
The average analyst price target for GH Research is $42.89, which corresponds to a potential gain of 99.3% from the current price of $21.52. The stock has traded between $12.04 and $31.44 over the last 52 weeks. The price is 31.6% below the 52-week high, which can indicate potential if the underlying fundamentals are intact. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can GH Research fall?
The stock has traded as low as $12.04 over the last 52 weeks — that is 44.1% below the current price of $21.52. The biggest decline (drawdown) in the same period was 61.7% from high to low. Within a year, the price typically swings about ±71.9% (standard deviation — a measure of price swings). A difficult year could therefore mean a further decline of that size. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does GH Research do?
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinic... The company belongs to the Healthcare sector, more specifically the Biotechnology industry, is headquartered in United States, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate GH Research as an investment.
Did GH Research raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from GH Research. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history above.
Is GH Research making money or losing money?
We have no current profitability data for GH Research. See the latest report in the earnings history above.
Can GH Research go bankrupt?
The bankruptcy risk of GH Research is rated as low. Altman Z2 (a model for assessing financial distress) is 32.81 — that places the company in the healthy zone. The company has a healthy balance sheet with limited debt relative to earnings and assets. The Piotroski score (financial health 0-9, higher is better) is 1 — which is weak. Debt relative to equity is 5% (low). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does GH Research have a lot of debt?
No, GH Research has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 5%. For the healthcare sector, anything below 80% counts as low debt. In healthcare, 80-150% is typical — large pharma companies carry debt for research and acquisitions. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
↑ Back to navigation

Other Stocks in Healthcare

Compare GH Research with other stocks in the healthcare sector. Click a stock to see its technical analysis, insider trading and key figures.

See all 106 stocks in the Healthcare sector

Explore More